The complete loss of the olaparib effect in the Brca2(−/−) model (in contrast to the Brca2(−/−)* model) could be due to tumour-promoting immune cells still being attracted to the Brca2(−/−) model by intact chemokine secretion in athymic mice lacking mature T cells. The gene discussed is BRCA2; the disease is neoplasm.